Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An update from Australian Clinical Labs Ltd ( (AU:ACL) ) is now available.
Australian Clinical Labs has disclosed a change in director Sarah Butler’s relevant interests, with Butler acquiring an indirect stake in the company through a trust structure. The transaction signals increased alignment between the director’s interests and shareholders, though the scale of the purchase suggests a modest financial impact on the company’s overall capital structure.
According to the notice, Butler, via Beausoleil Investments Pty Ltd as trustee for the Muskoka Trust, acquired 22,617 ordinary shares in an on-market trade at an average price of $2.21 per share. The acquisition brings her indirect holding in Australian Clinical Labs to 22,617 shares and reflects routine director share trading rather than any change to the company’s strategic direction or operations.
The most recent analyst rating on (AU:ACL) stock is a Hold with a A$2.40 price target. To see the full list of analyst forecasts on Australian Clinical Labs Ltd stock, see the AU:ACL Stock Forecast page.
More about Australian Clinical Labs Ltd
Australian Clinical Labs Limited operates in the pathology and diagnostic services industry in Australia, providing laboratory testing and related healthcare diagnostic services to clinicians, hospitals, and patients. The company’s operations focus on processing medical tests and supporting clinical decision-making across its national network of laboratories and collection centres.
Average Trading Volume: 662,368
Technical Sentiment Signal: Sell
Current Market Cap: A$422.9M
See more insights into ACL stock on TipRanks’ Stock Analysis page.